Redeye views the Q1 2025 report as solid and broadly in line with expectations.
Føroya Banki reports its Q1 2025 results on 30 April.
Atria's Q1 adjusted EBIT beat LSEG Data & Analytics consensus by 31%.
We lower adjusted EBITA by 6-13% for 2025E-27E following the Q1 report, which was weaker than expect...
Redeye believes investors overreacted to Enea’s Q1 2025 report, sending the stock down ~19% due to a...
Redeye updates its estimates following Waystream’s Q1 report, which was published yesterday.
Redeye provides an update following Iconovo’s Q1 2025 report.
Redeye makes slight changes to its Base Case and forecasts following the Q1 report.
The outdoor segment supports strong order bookings Minor estimate revisions '25e EV/EBIT ~7x Outdoo...
Q1 sales lower than expected due to weak end-markets in lightweight Expect positive EBIT margins in ...
Q1: Minor sales miss, but EBIT beat on strong GM We cut our sales estimates slightly, but raise adj.
Redeye comments on Vertiseit’s Q1 reporting, showing solid FX-adjusted ARR growth but somewhat soft ...
Tangiamo Touch Technology (”Tangiamo” eller ”Bolaget”) meddelade den 23 april år 2025 att Bolaget ha...
Redeye provides its initial take on OEM’s Q1 2025 report, which came in slightly below our estimates...
Sales -12%, adj. EBITA -60% vs. cons, -18% org. growth Consensus to lower '25e-'26e EBITA by 3-5% Sh...
Redeye provides a comment following Magle Group’s announcement of the acquisition of Swedish medtech...
Redeye provides a research update following the Q1 report published by Lipum earlier today.
Redeye comments on Powercell’s Q1 report which was mainly in line with our expectations.
Redeye was hoping for a bit more in terms of sales, although market conditions were far from ideal.
Net sales and EBIT were below market consensus (LSEG) in Q1.